MAGEA4 and neoplasm: On the personalized therapy front, neoantigen-based vaccines for POLE-mutant or MSI-H tumors, autologous dendritic cell (DC) vaccines—in which DCs are loaded ex vivo with tumor antigens and administered to stimulate specific T- and B-cell responses—as well as TCR-engineered therapies targeting cancer-testis antigens (NY-ESO-1, MAGE-A4), represent key frontiers (77).